 |
|
|
|
Board of Directors
 Edward J. Brennan, Jr., MD, FACS
Dr. Brennan is President and CEO of IndiPharm LLC
Prior to joining IndiPharm in early 2007, Dr. Brennan was Director of Clinical Pharmacology and Discovery Medicine at GlaxoSmithKline. At GSK, Dr. Brennan was responsible for coordinating all clinical activities for external partners within GSK’s Center of Excellence in External Drug Discovery (CEEDD). Prior to joining the CEEDD, Dr. Brennan was Director of Clinical Pharmacology within the MMPD CEEDD at GSK, where he was responsible for the development of multiple compounds from pre-Candidate Selection through to Proof of Concept. Before joining GSK, Dr. Brennan held clinical development positions of increasing responsibility at both Johnson & Johnson and Wyeth.
Dr. Brennan has extensive clinical development experience across all phases of clinical development, and across multiple therapeutic areas, including Oncology, Infectious Diseases, Immunology and Critical Care. He has led teams that have filed more than 10 Investigational New Drug Applications (IND), as well as multiple New Drug (NDA) and Supplemental New Drug Applications (SNDA).
Dr. Brennan received his undergraduate Bachelor of Science Degree in Pharmacy from The Philadelphia College of Pharmacy and Science. He went on to study medicine at The Royal College of Surgeons in Ireland before receiving his Medical Degree from Temple University School of Medicine. He completed his residency in General Surgery at the Lankenau Hospital and Medical Research Center, and after completing his fellowship in Advanced Minimally Invasive Surgery at the Minimally Invasive Surgical Training Institute (Baltimore, MD), he returned to join the staff at Lankenau, where he held a teaching appointment from Thomas Jefferson College of Medicine. While on the staff at Lankenau, Dr. Brennan also served as Surgical Residency Director.
 Mr. Vinay Sapte
Managing Executive of IndiPharm Operations, India
Mr. Sapte is Managing Director of Maneesh Pharmaceuticals, one of the fastest growing pharmaceutical companies in India. Maneesh is now one of the top 50 Indian manufacturing companies and offers specialized facilities and services for critical therapeutic segments like Anti-TB, Anti-malarial, Antibiotics, Pain Management, Infertility and Gynecology. Maneesh is well-known worldwide for the development of Anti-TB drugs and hormones and has dedicated facilities in Europe and India.
Mr. Sapte started Maneesh in 1975 as a small trading facility for providing biological raw materials, with a gradual expansion in manufacturing of generics followed by formulation and marketing of breakthrough brands. Over the period of three decades he has been the major driving force in the transformation of Maneesh from a small local enterprise to an international group of companies, growing and multiplying across the globe. Maneesh has developed innovative products for marketing by several leading pharmaceutical companies in India. A recent technological innovation was a combination of amoxicillin/clavulnate with lactic acid bacillus, a “first time in the world” initiative that is successfully marketed by Zuventus Healthcare Ltd.
Mr. Sapte established the Bombay Bioresearch Centre (BBRC) as a state of the art facility to conduct clinical trials for Maneesh. Over the years BBRC has become a world class clinical research facility with core competency in GCP and GMP requirements, and is compliant with requirements of the FDA (U.S.), MHRA (U.K), ANVISA (Brazil), Ministry of Health (Turkey), World Health Organization (Geneva, Switzerland), MCC (South Africa), and DCG (India).
 Dilip R. Limaye
Mr. Limaye is Founder and Chairman of IndiPharm and is responsible for business development, financial management, and overall corporate oversight and guidance. Mr. Limaye is an entrepreneur who has established a number of international organizations in a wide range of fields including energy efficiency, renewable energy, global climate change, information technology (IT), and business process outsourcing (BPO).
All of these ventures have involved the establishment of a U.S. based organization for client interface and client services combined with an Indian operation to execute projects and programs efficiently and effectively - thereby providing clients global quality services with a local U.S. interface at a substantially lower cost as compared to developed countries. After successfully implementing this business model in the fields of renewable energy, energy services, IT and BPO, Mr. Limaye created IndiPharm for effectively outsourcing clinical trials for biotech and pharmaceutical companies.
Mr. Limaye earned his Bachelor of Technology degree from one of the premier technology institution in the world, The Indian Institute of Technology (I.I.T.), Bombay, where he graduated #1 in his class and received the prestigious President of India Gold Medal. He earned his M.S. from Cornell University and has completed his Ph. D. candidacy examination in International business from the Wharton School, University of Pennsylvania. Mr. Limaye has published 6 books and has presented over 50 technical papers at national and international conferences. |
|
|
|
|
|
